Heidelberg Pharma AG reported earnings results for the second quarter and six months ended May 31, 2022. For the second quarter, the company reported sales was EUR 11.22 million compared to EUR 0.447949 million a year ago. Net loss was EUR 1.36 million compared to EUR 6.77 million a year ago. Basic loss per share from continuing operations was EUR 0.04 compared to EUR 0.22 a year ago.
For the six months, sales was EUR 11.93 million compared to EUR 0.818233 million a year ago. Revenue was EUR 12.17 million compared to EUR 1.08 million a year ago. Net loss was EUR 8.6 million compared to EUR 13.09 million a year ago. Basic loss per share from continuing operations was EUR 0.25 compared to EUR 0.42 a year ago.